Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:17:49.378Z.
Calculation as of: 2026-10-06T19:17:49.378Z.
Quote observation: 2026-10-06T19:12:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f827d960650d67e3900ac6098f04a5e2078fd3b8121965df68c70cd2fd602cdf
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$211.56M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$213.05M
Price/OCF Ratio
35.81
TTM Avg
45.91
3Y Avg
60.75
5Y Avg
60.42
Market Cap
$210.02M
Price/OCF Ratio
N/A
TTM Avg
4.01
3Y Avg
4.01
5Y Avg
4.01
Market Cap
$214.51M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$206.50M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$205.12M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $211.56M | N/A | N/A | N/A | N/A |
| Compugen Ltd. (CGEN)vs › | $210.68M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $213.05M | 35.81 | 45.91 | 60.75 | 60.42 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.02M | N/A | 4.01 | 4.01 | 4.01 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $211.72M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $214.51M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.86M | 28.70 | 26.60 | 21.85 | 26.58 |
| Sionna Therapeutics, Inc. (SION)vs › | $206.50M | N/A | N/A | N/A | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $205.12M | N/A | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $204.38M | N/A | 400.72 | 400.72 | 400.72 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
